Takeda Pharmaceutical (TAK) Other Non-Current Assets (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Other Non-Current Assets of $503.8 million for Q2 2026, up 6.33% year-over-year from $473.8 million in Q2 2025, and up 2.59% quarter-over-quarter from $491.1 million in Q1 2026.
Takeda Pharmaceutical (TAK) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $503.8 million for Q2 2026.
- In Q2 2026, Other Non-Current Assets rose 6.33% year-over-year to $503.8 million; the TTM figure through Jun 2026 stood at $503.8 million (up 6.33% YoY), while the FY2026 annual figure was $511.6 million, up 10.88% from the prior year.
- Other Non-Current Assets for Q2 2026 stood at $503.8 million, up from $491.1 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $710.9 million in Q1 2022, with the low at $345.6 million in Q1 2024.
- The 5-year median for Other Non-Current Assets is $483.3 million (2024), against an average of $506.8 million.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets slumped 32.97% in 2023, then soared 55.3% in 2024.
- Takeda Pharmaceutical's Other Non-Current Assets stood at $472.6 million in 2022, then dropped by 21.7% to $370.1 million in 2023, then soared by 31.81% to $487.8 million in 2024, then grew by 3.63% to $505.5 million in 2025, then retreated by 0.34% to $503.8 million in 2026.
- Business Quant data shows TAK's Other Non-Current Assets at $503.8 million in Q2 2026, $491.1 million in Q1 2026, and $505.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | 13.00 Mn |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | 62.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 503.80 Mn |
| Mar 31, 2026 | 491.06 Mn |
| Dec 31, 2025 | 505.52 Mn |
| Sep 30, 2025 | 478.68 Mn |
| Jun 30, 2025 | 473.79 Mn |
| Mar 31, 2025 | 460.67 Mn |
| Dec 31, 2024 | 487.79 Mn |
| Sep 30, 2024 | 569.96 Mn |
| Jun 30, 2024 | 681.56 Mn |
| Mar 31, 2024 | 345.58 Mn |
| Dec 31, 2023 | 370.08 Mn |
| Sep 30, 2023 | 413.19 Mn |
| Jun 30, 2023 | 438.86 Mn |
| Mar 31, 2023 | 478.73 Mn |
| Dec 31, 2022 | 472.65 Mn |
| Sep 30, 2022 | 584.30 Mn |
| Jun 30, 2022 | 654.76 Mn |
| Mar 31, 2022 | 710.86 Mn |
| Dec 31, 2021 | 700.66 Mn |
| Sep 30, 2021 | 856.52 Mn |